"Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared
Research Grant
Administered By
Pediatrics, Cardiology
Awarded By
Novartis Pharma AG
Start Date
January 1, 2016
End Date
September 30, 2021
Administered By
Pediatrics, Cardiology
Awarded By
Novartis Pharma AG
Start Date
January 1, 2016
End Date
September 30, 2021